Uttarakhand: SIT to probe fake Covid testing during Kumbh

By: |
June 19, 2021 9:15 AM

One of the world's largest religious gatherings, the Kumbh was held in the state from April 1 to 30, and the notified area for the congregation covered various places in Haridwar, Dehradun and Tehri districts.

Uttarakhand Police , SIT, fake Covid tests, Haridwar, Dehradun and Tehri districts., speedy probe, Max Corporate Service, Epidemic Act , the Disaster Management ActThe SIT has been constituted for a speedy probe.

.The Uttarakhand Police has set up a special investigation team to probe allegations that fake Covid tests were conducted during the Haridwar Kumbh Mela.

One of the world’s largest religious gatherings, the Kumbh was held in the state from April 1 to 30, and the notified area for the congregation covered various places in Haridwar, Dehradun and Tehri districts.

The special investigation team (SIT) was constituted by Haridwar Senior Superintendent of Police Senthil Avoodai Krishna Raj S on Friday, a day after a case was registered against Max Corporate Service and private laboratories Dr Lalchandani Lab and Nalwa Laboratories for allegedly conducting the fake Covid tests during the Kumbh.

The SIT has been constituted for a speedy probe, Krishna Raj said.

Max Corporate Service and the two other labs have been booked under the Epidemic Act , the Disaster Management Act besides sections 120 B (criminal conspiracy to commit an offence punishable) and 420 (cheating) of the Indian Penal Code.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: Officials in Tokyo alarmed as coronavirus cases hit record highs
2Biocon Biologics, Viatris get USFDA nod for 1st interchangeable biosimilar insulin product
3Covid-19: Six-member central team to visit Kerala as it still reports high number of cases